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Background
Multiple strengths of mometasone furoate/formoterol
(MF/F) MDI combination therapy are under investiga-
tion as new treatments for asthma. We report efficacy/
safety findings from a 3-month MF/F study in subjects
with severe asthma.
Materials and methods
This was a 3-month, randomized, double-blind, parallel-
group, multicenter study with a 2-3-week open-label,
run-in period of mometasone furoate (MF) 400 μg
twice-daily (BID). Subjects (≥12 years) were randomized
to MF/F (200/10 μg or 400/10 μg BID) or MF (400 μg
B I D ) .T h ep r i m a r ye n d p o i n tw a st h ea r e au n d e rt h e
c u r v e( A U C )o ft h ec h a n g ei ns e r i a lF E V 1 (0-12 hours)
for MF/F 400/10 μg vs MF 400 μg from baseline to
Week 12. Adverse events (AEs) and other clinical safety
measures were recorded.
Results
A total of 728 subjects (mean: age = 47.9 y, asthma dura-
tion = 14.0 y, FEV1 % predicted = 66.3, reversibility =
22.9%, Asthma Control Questionnaire [ACQ] score =
1.93) were randomized. Improvements in mean changes
from baseline in FEV1 AUC0-12 h ( L×h )a tW e e k1 2
were MF/F 200/10 μg = 3.59, MF/F 400/10 μg = 4.19,
and MF 400 μg = 2.04, with both MF/F doses signifi-
cantly better than MF (p < 0.001). These FEV1s
correspond to average hourly increases of 0.30, 0.35, and
0.17 L, respectively. MF/F was associated with rapid
(<5 min) and sustained improvement in lung function.
The percentage of subjects experiencing asthma dete-
rioration (ie, severe asthma exacerbation) was 12.4%
(MF/F 200/10 μg), 12.2% (MF/F 400/10 μg), and 18.3%
(MF 400 μg). There were no notable differences in AEs
between the groups.
Conclusions
Both medium- and high-dose MF/F combination ther-
apy led to significantly greater improvements in lung
function compared with high-dose MF monotherapy in
severe asthmatics.
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